2006
DOI: 10.1038/sj.leu.2404351
|View full text |Cite
|
Sign up to set email alerts
|

Downregulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
24
0

Year Published

2009
2009
2018
2018

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 30 publications
(24 citation statements)
references
References 25 publications
(42 reference statements)
0
24
0
Order By: Relevance
“…Stable down regulation (8, Supplementary Figure S2) of either topo IIα (72 ± 7.2%) or topo IIβ (96 ± 4.1%) in HL-60 cells (HL-60/sitopo IIα or HL-60/sitopo IIβ, respectively) led to an increase in the pseudomitotic index compared to control cells (HL-60/siGFP) (Figure 3A), confirming that the decatenation checkpoint is regulated by both topo IIα and topo IIβ and is most efficient when both isoforms are present. Our results demonstrating a higher pseudomitotic index in topo IIβ-deficient cells (HL-60/si-topo IIβ), which express higher levels of topo IIα and lower levels of topo IIβ compared to topo IIα-deficient cells, supports our finding in HTETOP cells that the topo IIβ isoform may be more proficient in regulating the decatenation checkpoint.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Stable down regulation (8, Supplementary Figure S2) of either topo IIα (72 ± 7.2%) or topo IIβ (96 ± 4.1%) in HL-60 cells (HL-60/sitopo IIα or HL-60/sitopo IIβ, respectively) led to an increase in the pseudomitotic index compared to control cells (HL-60/siGFP) (Figure 3A), confirming that the decatenation checkpoint is regulated by both topo IIα and topo IIβ and is most efficient when both isoforms are present. Our results demonstrating a higher pseudomitotic index in topo IIβ-deficient cells (HL-60/si-topo IIβ), which express higher levels of topo IIα and lower levels of topo IIβ compared to topo IIα-deficient cells, supports our finding in HTETOP cells that the topo IIβ isoform may be more proficient in regulating the decatenation checkpoint.…”
Section: Resultsmentioning
confidence: 99%
“…These cDNAs were cloned in the pHT212 plasmid and transformed in the Saccharomyces cerevisiae yeast strain, BJ201, for preparing recombinant protein for in vitro decatenation assay as described earlier (22,23). The cDNAs were also cloned in the neo-containing IRES-enhanced green fluorescent protein expression pEIE vector described earlier (8) for expressing the recombinant proteins in the genetically engineered fibrosarcoma cell line, HTETOP (25) and in the m -AMSA-resistant HL-60 cell line (HL-60/AMSA-R), which does not express the topo IIβ protein (8,26). …”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…43 In addition, Prdx2 has been reported to have an important role in the inhibition of apoptosis in a novel pathway distinct from Bcl-2. 44,45 The increased expression of Prdx2 following treatment with pCons might shed light on the mechanism by which peptide tolerization decreases apoptosis.…”
Section: Discussionmentioning
confidence: 99%
“…The PRDX2 is a peroxidoreductase that catalyzes oxidation-reduction reactions and has been implicated in Down's syndrome [72], Alzheimer's disease [73] and various forms of neoplasms [74]. The protein may be involved in the regulation of apoptosis and response to oxidative stress [75], possibly by influencing oxidoreductase enzyme activities [67,69,76], among others. The CRYM has also been associated with various forms of cancer [77].…”
Section: Discussionmentioning
confidence: 99%